ATE532874T1 - Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen - Google Patents

Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Info

Publication number
ATE532874T1
ATE532874T1 AT06024213T AT06024213T ATE532874T1 AT E532874 T1 ATE532874 T1 AT E532874T1 AT 06024213 T AT06024213 T AT 06024213T AT 06024213 T AT06024213 T AT 06024213T AT E532874 T1 ATE532874 T1 AT E532874T1
Authority
AT
Austria
Prior art keywords
disease
protein
yeast
detecting
protein folding
Prior art date
Application number
AT06024213T
Other languages
English (en)
Inventor
Susan Lindquist
Sylvia Krobitsch
Tiago Outeiro
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23026039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532874(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of ATE532874T1 publication Critical patent/ATE532874T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
AT06024213T 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen ATE532874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26915701P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ATE532874T1 true ATE532874T1 (de) 2011-11-15

Family

ID=23026039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02718994T ATE382704T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
AT06024213T ATE532874T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02718994T ATE382704T1 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Country Status (8)

Country Link
US (7) US7045290B2 (de)
EP (2) EP1392849B2 (de)
JP (2) JP4344138B2 (de)
AT (2) ATE382704T1 (de)
AU (3) AU2002250102B2 (de)
CA (1) CA2438661C (de)
DE (1) DE60224383T3 (de)
WO (1) WO2002065136A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
KR20050053607A (ko) * 2002-08-07 2005-06-08 유니버시티 오브 델라웨어 단백질 오조립 및 응집을 나타내는 질병을 치료하기 위한조성물 및 방법
FR2846009B1 (fr) 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
FR2846008B1 (fr) * 2002-10-18 2006-06-02 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
CA2522497A1 (en) * 2003-04-16 2004-11-04 Whitehead Institute For Biomedical Research Yeast ectopically expressing abnormally processed proteins and uses therefor
EP3211084B1 (de) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US20060008894A1 (en) * 2003-07-11 2006-01-12 Gerard Griffioen Yeast model for amyloidogenic protein toxicity
US7452670B2 (en) 2003-12-04 2008-11-18 University Of Washington Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast
WO2005108599A2 (en) * 2004-05-05 2005-11-17 Whitehead Institute For Biomedical Research Compositions and methods for treatment of protein misfolding diseases
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
EP1754052B1 (de) * 2004-06-03 2015-07-22 Phylogica Limited Modulatoren biochemischer eigenschaften
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide
US7504227B2 (en) * 2004-10-20 2009-03-17 University Of Washington Drug targets for the treatment of neurodegenerative disorders
JP4939432B2 (ja) 2004-12-01 2012-05-23 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ α−シヌクレイン毒性のモジュレーター
US9018003B2 (en) 2005-05-13 2015-04-28 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US7368258B1 (en) * 2005-06-06 2008-05-06 University Of Maryland, Baltimore County Devices and methods for profiling enzyme substrates
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
GB0610792D0 (en) * 2006-06-02 2006-07-12 Remynd Nv Methods and tools for the screening of factors affecting protein misfolding
CA3009034C (en) 2006-10-10 2020-08-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2008067070A2 (en) 2006-10-19 2008-06-05 California Institute Of Technology Compositions and methods for producing benzylisoquinolines alkaloids
US8323952B2 (en) * 2007-12-13 2012-12-04 Archer Daniels Midland Company Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast Hansenula polymorpha
WO2009086306A1 (en) 2007-12-21 2009-07-09 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US9738898B2 (en) 2008-02-15 2017-08-22 Whitehead Institute For Biomedical Research Yeast cells expressing TAR DNA-binding protein 43 and uses therefor
ES2418459B1 (es) * 2008-10-09 2014-08-12 Universitat Autònoma De Barcelona Relacionando agregación proteica con supervivencia de levadura
US8865411B2 (en) 2009-03-26 2014-10-21 National Institutes Of Health (Nih) Methods of identifying modulators of TDP-43 mediated cellular toxicity
EP2524040B1 (de) 2010-01-12 2017-03-15 The Whitehead Institute for Biomedical Research Hefezellen zur expression von amyloid-beta und verwendungen davon
CN101858910B (zh) * 2010-03-25 2013-03-27 辽宁大学 一种在蛋白质水平精确定量检测抗朊病毒药物作用效果的方法
CA2875348A1 (en) * 2012-06-01 2013-12-05 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
US10642376B2 (en) 2012-11-28 2020-05-05 Intel Corporation Multi-function stylus with sensor controller
HK1220233A1 (zh) * 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
DK3553177T3 (da) 2013-03-15 2021-02-15 Univ Leland Stanford Junior Benzylisoquinolinalkaloider (bia) som producerer mikrober, og fremgangsmåder til fremstilling og anvendelse deraf
CN112410379B (zh) 2013-11-04 2024-12-31 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物以及制备和使用所述前体的方法
CH709681A1 (de) 2014-05-21 2015-11-30 Explo Engineering Ag Pulsdetonationsantrieb.
EP3155003B9 (de) 2014-06-13 2020-12-30 Whitehead Institute for Biomedical Research Amyloid-beta-expression-konstrukte und verwendungen davon
CA2954738A1 (en) * 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
EP3191578B1 (de) * 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Zellen zur expression von apolipoprotein e und verwendungen davon
WO2016081371A1 (en) 2014-11-17 2016-05-26 The Board Of Trustees Of The Leland Stanford Junior University Noscapinoid-producing microbes and methods of making and using the same
EP3292203A4 (de) 2015-05-04 2019-10-09 The Board of Trustees of the Leland Stanford Junior University Benzylisochinolin-alkaloid (bia)-vorläufer produzierende mikroben sowie verfahren zur herstellung und verwendung davon
JP7266966B2 (ja) 2015-05-08 2023-05-01 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー エピメラーゼ及びベンジルイソキノリンアルカロイドを産生する方法
US11674952B2 (en) 2016-02-24 2023-06-13 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
EP3566055B1 (de) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd-hemmer zur behandlung von neurologischen erkrankungen
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2019028390A1 (en) 2017-08-03 2019-02-07 Antheia, Inc. ALKALOID BENZYLISOQUINOLEIN GENETICALLY MODIFIED EPIMERASES AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS
US10550550B2 (en) * 2017-09-13 2020-02-04 Dominic P. Ismert Modular two-part sillcock
US20200255487A1 (en) * 2017-10-12 2020-08-13 The Regents Of The University Of California A Cell-Based Seeding Assay for Huntingtin Aggregation
US10649550B2 (en) 2018-06-26 2020-05-12 Intel Corporation Predictive detection of user intent for stylus use
CN120399912A (zh) 2019-03-08 2025-08-01 小利兰·斯坦福大学托管委员会 产生莨菪烷生物碱(ta)的非植物宿主细胞及其制备和使用方法
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
WO2023284782A1 (zh) * 2021-07-14 2023-01-19 复旦大学 筛选用于治疗或预防mHTT相关的神经退行性疾病的化合物的方法，靶蛋白，以及化合物
US20250093332A1 (en) * 2022-01-12 2025-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Methods and related aspects of quantifying protein stability and misfolding
CN114990049B (zh) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 一种同时调节细胞表达产物的糖型和电荷异质性的方法
EP4594342A2 (de) 2022-09-29 2025-08-06 Antheia, Inc. Verfahren zur verbesserung der produktion von morphinan-alkaloiden und derivaten
DE202022107272U1 (de) 2022-12-28 2023-01-30 Centurion University of Technology and Management Ein System zur Analyse der Infektion mit Pseudomonas Syringae durch gezielte Ansprache von Cochaperonen, die eine J-Domäne enthalten
WO2024172061A1 (ja) * 2023-02-17 2024-08-22 国立大学法人京都大学 Ｒｎａアプタマー
GB202315164D0 (en) 2023-10-03 2023-11-15 Univ Edinburgh Nanochromosome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
WO1991004339A1 (en) * 1989-09-18 1991-04-04 California Biotechnology Inc. Assays and reagents for amyloid deposition
GB8921791D0 (en) 1989-09-27 1989-11-08 Imp Cancer Res Tech Disease gene
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
DE4204650C1 (de) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6093549A (en) 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
DE69842048D1 (de) 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
US5952217A (en) * 1997-09-23 1999-09-14 Bristol-Myers Squibb Company Recombinant yeast cell and assay using same
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US20010006793A1 (en) * 1998-03-20 2001-07-05 Mary-Ann Bjornsti Modulators of eukaryotic caspases
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
CA2372742A1 (en) 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Double transgenic animals as models for neurodegenerative disease
EP1204674A4 (de) * 1999-07-27 2005-06-01 Abgenix Inc Methoden und verbindungen zur verhinderung von polypeptid-ansammlungen im zusammenhang mit neurologischen störungen
US6420122B1 (en) 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
GB0104685D0 (en) * 2001-02-26 2001-04-11 Leuven K U Res & Dev Tau-opathy model
AU2002310497A1 (en) * 2001-06-20 2003-01-08 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
US20060008894A1 (en) 2003-07-11 2006-01-12 Gerard Griffioen Yeast model for amyloidogenic protein toxicity

Also Published As

Publication number Publication date
US20130005608A1 (en) 2013-01-03
EP1392849B2 (de) 2012-01-18
EP2319936A2 (de) 2011-05-11
US20060147902A1 (en) 2006-07-06
EP1392849B1 (de) 2008-01-02
JP5152977B2 (ja) 2013-02-27
CA2438661C (en) 2011-05-31
DE60224383T2 (de) 2009-01-08
AU2007221933B2 (en) 2010-12-16
JP4344138B2 (ja) 2009-10-14
WO2002065136A3 (en) 2003-12-11
AU2002250102B2 (en) 2007-07-12
US20030073610A1 (en) 2003-04-17
US20140273074A1 (en) 2014-09-18
US20060141449A1 (en) 2006-06-29
AU2007221933A1 (en) 2007-11-01
EP2319936A3 (de) 2012-10-17
JP2004537973A (ja) 2004-12-24
US7045290B2 (en) 2006-05-16
US20170306386A1 (en) 2017-10-26
DE60224383D1 (de) 2008-02-14
JP2008259509A (ja) 2008-10-30
US20110300533A1 (en) 2011-12-08
US9518284B2 (en) 2016-12-13
US8039209B2 (en) 2011-10-18
AU2011200744A1 (en) 2011-03-17
DE60224383T3 (de) 2012-06-28
ATE382704T1 (de) 2008-01-15
EP1392849A2 (de) 2004-03-03
AU2011200744B2 (en) 2013-04-04
CA2438661A1 (en) 2002-08-22
WO2002065136A2 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
ATE532874T1 (de) Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
AU8448301A (en) Remedies for heart failure
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
ATE548453T1 (de) Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
DE60330985D1 (de) Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
BR0312282A (pt) Processo para o enriquecimento e detecção de proteìnas de priÈnios patologicamente modificadas (prpsc)
EP1793001A3 (de) Verfahren zum Nachweis in Hefe für mittels die Proteinfaltung beeinflussen
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2006091964A8 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2003093442A3 (en) Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
WO2003087408A3 (en) Schizophrenia associated genes
WO1999006838A3 (en) Novel method of detecting amyloid-like fibrils or protein aggregates
TW200801190A (en) Regulators of protein misfolding and aggregation and methods of using the same
GB2382579B (en) Disease models, assays, methods and means
NO20091627L (no) Fremgangsmate for identifisering av potensielle biomarkorer og medikamentmal i hjerneplastisitetsrelaterte forstyrrelser